A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
A doggy intelligence test may hold the key to a better understanding of human health problems like dementia, scientists say.
The Duchess says that children should be "supported through difficult times in their lives" at the start of Children's Mental Health Week.
The Met Police could soon be using birds of prey to help keep the skies above London clear of crime.